This tool is for research exploration only. It is not a medical device and does not provide medical advice. Drug candidates, evidence scores, and AI-generated content are not clinical recommendations. Always consult your medical team before making any treatment decisions.

Back to Drug Candidates

Bevacizumab

Avastin

Anti-VEGF monoclonal antibody

Evidence Score

65

established
Mechanism of Action

Humanized monoclonal antibody that binds VEGF-A, preventing its interaction with VEGFR. Blocks tumor angiogenesis. Has shown activity in SDH-deficient paragangliomas in combination with temozolomide.

Pathway Connections
VEGF Signaling

Downstream of HIF activation, VEGF/VEGFR2 signaling drives tumor angiogenesis — the formation of new blood vessels that supply the tumor with oxygen and nutrients.

Upstream event:

HIF-mediated VEGFA transcriptional activation

Downstream effects:

Tumor angiogenesisVascular permeabilityEndothelial cell proliferationTumor blood supply
Molecular Targets

VEGFA

Vascular endothelial growth factor A

downstream

Key HIF target gene driving tumor angiogenesis. Target of bevacizumab.

UniProt: P15692

Quick Facts
FDA Approved

Approved Indications

  • Metastatic colorectal cancer
  • Non-small cell lung cancer
  • Glioblastoma
  • Renal cell carcinoma
ChEMBL IDCHEMBL1201583
Evidence

Evidence from PubMed, OpenTargets, and ChEMBL will appear here once external data integration is enabled.

Coming in Phase 3

For research exploration only — not medical advice. Consult your doctor before acting on any information.

AI Analysis

Have Claude analyze this drug's repurposing potential for SDH-deficient diseases.